Many analysts have voiced fears that the U.S. stock markets march higher is overdone.
One chart watcher, on the other hand, is suggesting the opposite.
The breakout could be just getting started, wrote Jonathan Krinsky, chief market technician at MKM Partners, in a note dated Sunday.
This view comes after Krinsky looked not at the S&P 500
or the Dows
30 blue chips, but rather at the Value Line Geometric Index
, which consists of about 1,675 U.S. stocks.
Hot Blue Chip Stocks To Invest In 2018: Arc Wireless Solutions Inc.(ARCW)
- [By Jim Robertson]
On Thursday, our Under the Radar Moversnewsletter suggested small cap manufacturing and 3D printing service provider ARC Group WorldWide (NASDAQ: ARCW) as a short trade:
Hot Blue Chip Stocks To Invest In 2018: Lincoln National Corporation(LNC)
- [By Lee Jackson]
Lincoln National Corp. (NYSE: LNC) also had the man at the top selling stock last week. Dennis Glass, the CEO of this insurance and retirement focused company, sold a block of 75,000 shares at between $71.00 and $71.28 apiece. The total for the sale was posted at $5 million. Shares closed Friday at $71.69, in a 52-week rangeof $34.16 to $73.71. The consensus price target is $73.17.
- [By WWW.THESTREET.COM]
* The market bent yesterday but today it stabilized. (A good showing, all things being considered–but in no way decisive going forward).
* Gold +$5/oz.
* Crude oil +$0.50 and the rise is taking up some energy stocks.
* The Russell returned to the spotlight.
* Life insurance–particularly Lincoln National (LNC) (on an upgrade). Hartford Financial Services (HIG) gets a small lift.
* Retail returned from the depths. The standouts–L Brands (LB) , Kohl’s (KSS) , Bed Bath (BBBY) , Nordstrom (JWN) and Gap (GPS) .
* Ag equipment–after an analyst upgrade yesterday.
* Homebuilders catch a bid.
* Day one of the Masters Golf Tournament.
Hot Blue Chip Stocks To Invest In 2018: Ishares Trust Dj Us Financial (IYF)
- [By Wayne Duggan]
Investors looking to set up a pair trade to capitalize on the divergent paths of U.S. and European banks should consider going long the iShares Dow Jones US Financial (ETF) (NYSE: IYF) and short the Ishares MSCI Europe Fincls Sctr Indx Fd (NASDAQ: EUFN).
Hot Blue Chip Stocks To Invest In 2018: Sinovac Biotech Ltd.(SVA)
- [By Monica Gerson]
Sinovac Biotech Ltd. (NASDAQ: SVA) is expected to post its quarterly earnings.
Supercom Ltd (NASDAQ: SPCB) is estimated to post its quarterly earnings at $0.15 per share on revenue of $9.03 million.
Hot Blue Chip Stocks To Invest In 2018: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Lisa Levin]
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.
- [By Cory Renauer]
Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.
- [By Chris Dier-Scalise]
On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.
- [By Ben Levisohn]
Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.
Hot Blue Chip Stocks To Invest In 2018: Vanguard Mega Cap Growth ETF (MGK)
- [By Todd Shriber, ETF Professor]
Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).